Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 18/20 | 0.70 |
| ▸ | NPY1R | P25929 | 11/20 | 0.70 |
| ▸ | NPY5R | Q15761 | 10/20 | 0.70 |
| ▸ | NPY2R | P49146 | 7/20 | 0.70 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29947137 | 1.00 | NPY4R (0.70) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL30464863 | 0.94 | NPY4R (0.64) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL241712 | 0.94 | NPY4R (0.64) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL241711 | 0.94 | NPY4R (0.64) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL30939366 | 0.92 | NPY4R (0.61) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL30939364 | 0.92 | NPY4R (0.61) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL30647286 | 0.91 | NPY4R (0.63) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30099543 | 0.91 | NPY4R (0.63) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29947085 | 0.91 | NPY4R (0.63) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL31222384 | 0.91 | NPY4R (0.62) | NPY4RNPY1RNPY5RNPY2RKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12365706-B2 | Macrocyclic peptides as potent inhibitors of K-RAS G12D mutant | MERCK SHARP & DOHME LLC (US) | 2025-07-22 | — | — | US | disclosed |
| US-20230083431-A1 | MACROCYCLIC PEPTIDES AS POTENT INHIBITORS OF K-RAS G12D MUTANT | MERCK SHARP & DOHME LLC (US) | 2023-03-16 | — | — | US | disclosed |
| EP-4076493-A1 | MACROCYCLIC PEPTIDES AS POTENT INHIBITORS OF K-RAS G12D MUTANT | Merck Sharp & Dohme LLC (US) | 2022-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12365706-B2 | Macrocyclic peptides as potent inhibitors of K-RAS G12D mutant | KRAS, NRAS, HRAS | NPY4R 3808/4885NPY1R 3030/4885NPY5R 3284/4885 |
| US-20230083431-A1 | MACROCYCLIC PEPTIDES AS POTENT INHIBITORS OF K-RAS G12D MUTANT | KRAS, NRAS, HRAS | NPY4R 3808/4885NPY1R 3030/4885NPY5R 3284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.